Researchers at Kanazawa University report a blood-based diagnostic approach that could make early pancreatic cancer screening more feasible and improve patient outcomes. Pancreatic ductal adenocarcinoma remains lethal in part because early-stage disease is rarely detected—only about 2–3% of diagnoses occur at an early enough stage for curative surgery. In Japan, the five-year relative survival rate is just 8.5%, underscoring the need for less invasive, earlier detection tools.
The team previously developed “Panregza,” a test that combines peripheral whole-blood gene expression patterns with the serum tumor marker CA19-9. While Panregza has shown utility in later-stage disease, its performance in stage 0–Ⅰ cancers—where tumor burden is minimal—had not been established.
In the current pilot case–control study, the researchers analyzed whole-blood mRNA expression using a panel of 56 gene probes. They evaluated stage 0–Ⅰ pancreatic cancer samples from 10 patients (about 4% of a larger cohort) and compared them with 104 healthy individuals. Diagnostic performance was assessed for (1) gene expression alone, (2) CA19-9 alone, and (3) the combined Panregza system.
The blood gene expression method identified 9 of 10 early-stage cases, corresponding to 90% sensitivity. By contrast, CA19-9 detected only 1 of 10 cases, or 10% sensitivity, highlighting the limitation of relying on tumor marker levels for early disease.
When CA19-9 was combined with the gene expression readout, the Panregza system achieved 60% sensitivity and 93.3% specificity. Together, these results suggest that peripheral whole-blood transcriptional signatures carry clinically meaningful information even when CA19-9 is normal.
Importantly, the findings support a biological model in which pancreatic cancer-associated signaling alters gene expression in immune and other blood cell populations. Because these changes can occur before substantial tumor growth, they may enable detection that is not dependent on tumor volume.
The study also emphasizes the clinical significance of early diagnosis. At Kanazawa University Hospital’s Innovative Research and Development Center for Pancreatic Cancer, reported five-year survival rates are 100% for stage 0 and 74.4% for stage Ⅰ, reflecting the impact of catching disease early.
Overall, the work provides viral-science-news momentum for whole-blood mRNA diagnostics in pancreatic cancer and strengthens the case for further validation toward scalable screening.
Subject of Research: Whole-blood mRNA expression diagnostic system for early-stage pancreatic ductal adenocarcinoma (Panregza)
Article Title: Pilot validation of a whole-blood mRNA expression-based diagnostic system for early-stage pancreatic ductal adenocarcinoma: a single-center case–control diagnostic accuracy study
News Publication Date:
Web References: https://doi.org/10.1038/s41598-026-58684-8
References: 10.1038/s41598-026-58684-8
Image Credits: © Kanazawa University
Keywords: pancreatic cancer; early detection; whole-blood mRNA; gene expression; CA19-9; diagnostic accuracy; biomarker; Panregza; sensitivity; specificity; immune-associated transcriptional signatures
Tags: blood test sensitivity for early cancerblood-based pancreatic cancer screeningearly pancreatic tumor biomarkersearly-stage pancreatic cancer detectiongene expression profiling for pancreatic cancerimproving pancreatic cancer survival ratesminimally invasive cancer diagnosticsmRNA blood test for cancernon-invasive cancer detection methodspancreatic ductal adenocarcinoma diagnosisPanregza diagnostic testserum tumor marker CA19-9
